Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18349668 | 0.79 | LMNA (0.46) | LMNAMCL1ALDH1A1KMT2A | |
| SCHEMBL29329059 | 0.79 | ALDH1A1 (0.32) | LMNAALDH1A1MAPT | |
| SCHEMBL181668 | 0.78 | CYP2D6 (0.36) | ALDH1A1 | |
| SCHEMBL14595129 | 0.78 | HDAC8 (0.42) | — | |
| SCHEMBL8909886 | 0.76 | MEN1 (0.45) | LMNAALDH1A1KMT2A | |
| SCHEMBL14595133 | 0.76 | CTSD (0.44) | LMNAALDH1A1MAPT | |
| SCHEMBL6812643 | 0.76 | — | — | |
| SCHEMBL9282807 | 0.76 | CYP2D6 (0.35) | ALDH1A1 | |
| SCHEMBL28708081 | 0.76 | CYP2D6 (0.35) | ALDH1A1 | |
| SCHEMBL7142603 | 0.76 | CYP2D6 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633371-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| WO-2017184999-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-7989430-B2 | Antibacterial agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-08-02 | — | — | US | disclosed |
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0600831-A1 | Phtalazinon derivatives | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| EP-0600830-A1 | Substituted derivatives of diaminophthalimide as protein-tyrosine kinase inhibitors | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| EP-0600832-A1 | Derivatives of diamino benzoic and diamino phthalic acid und their use as protein linase inhibitors | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
| US-5292949-A | Process for the preparation of acid anhydrides | SAUREFABRIK SCHWEIZERHALL (CH) | 1994-03-08 | — | — | US | disclosed |
| EP-0549531-A1 | Process for preparing acid anhydrides | Säurefabrik Schweizerhall (CH) | 1993-06-30 | — | — | EP | disclosed |
| EP-0532466-A2 | Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | LMNA 1339/4885MCL1 484/4885SLC6A3 4749/4885 |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | LMNA 3064/4885MCL1 1457/4885SLC6A3 3336/4885 |
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | LMNA 2342/4885MCL1 121/4885SLC6A3 4672/4885 |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | LMNA 2342/4885MCL1 121/4885SLC6A3 4672/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | LMNA 2786/4885MCL1 1529/4885SLC6A3 3321/4885 |
| US-10633371-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | LMNA 2342/4885MCL1 121/4885SLC6A3 4672/4885 |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | KRAS, NRAS, HRAS | LMNA 1339/4885MCL1 484/4885SLC6A3 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.